Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 102 results for "Byetta"

Researchers find anti-diabetic drug not harmful to heart, as previous study found
University of Manitoba

Diabetes drug may help treat cocaine addiction: study

and type 2 diabetics may also help treat cocaine dependence, a new study has claimed. The drug, Byetta, is derived from a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which regulates feeding behaviour. Knowing what they did about ... Business Standard, 2 months ago

Byetta improves liver metabolism in patients with NAFLD

BARCELONA — Byetta, a glucagon-like peptide-1 agonist approved for the treatment of type 2 diabetes mellitus, improved hepatic insulin resistance and adipose tissue in men with nonalcoholic fatty liver disease, according to a poster presentation ...
 Healio2 weeks ago

AstraZeneca PLC AZN: 1st Quarter Results

Q1 2016 Results Financial Summary $m % change --------------------- ------ ---------------- CER(1) Actual --------------------- ------ ------- ------- Total Revenue(2) 6,115 5 1 --------------------- ------ ------- ------- Core(3) Op. Profit ...
 ADVFN UK10 hours ago

Antidiabetics Market 2016-2020 Industry exmined by Syndicate Market Research

Diabetes mellitus, commonly known as diabetes, is a group of metabolic diseases in which blood sugar levels goes extremely high over a prolonged period. Antidiabetics are the medicines developed to stabilize and control blood glucose (sugar) levels ...
 International Business Times2 days ago Global Diabetes Injection Pens Market 2016 Industry Analysis, Segment & Forecast up to 2014 2020  Minyanville3 weeks ago Global Antidiabetics Market 2016 Industry Analysis, Segment & Forecast up to 2014 2020  BioSpace3 weeks ago Diabetes Injection Pens Market - Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 2020  Digital Journal1 month ago

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

(GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the report to their offering. Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects ...
 Benzinga.com4 days ago Asia-Pacific Type 2 Diabetes Mellitus Therapeutics In Markets To 2021 - Markets Is Expected To Increase In Value At A CAGR Of 7.7%, From $6.07 Billion To Over $10.2 Billion - Research And Markets  TheStreet.com3 days ago Peptide Therapeutics in Metabolic Disorders, 2016 - 2025  MarketResearch.com2 months ago Global Peptide Therapeutics in Metabolic Disorders 2016-2025 [Daily Tribune (Bahrain)]  Pharmacy Choice2 months ago

Eli Lilly cuts ties with Transition, ends diabetes drug collaboration

Dive Brief: Eli Lilly has dropped a collaboration deal with Toronto-based Transition Therapeutics, choosing to not advance a type 2 diabetes drug into Phase 3, Transition disclosed on Monday. With this decision, Lilly gives worldwide development ...
 BioPharma Dive1 week ago

Type 2 Diabetes Market To 2019 - A Shifting Treatment Algorithm And Intensified Competition Expected To Drive Growth By 2019

(MENAFN Press) "The Report Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 provides information on pricing market analysis shares forecast and company profiles for key ...
 MENAFN1 week ago Type 2 Diabetes Market to 2019 - Excepted Highest Growth by 2019  Digital Journal1 week ago

List of Sales of Diabetes Drugs in 2015

Trade name Manufacturer Sales/USD100 million Growth Lantus (insulin glargine) Sanofi 71.84 -10.8% Januvia (sitagliptin) MSD 38.63 -2% NovoRapid/NovoLog (insulin aspart/insulin detemir) ...
 CPhI.cn2 weeks ago
Medical News Today

No increased heart failure with incretin-based drugs

Canadian drug safety network provides reassuring evidence regarding risk of heart failure of anti-diabetes medications Incretin-based drugs (which include the DPP-4 inhibitors Galvus, Jalra, Januvia, Nesina, Onglyza, Trajenta, and Xiliarx, as well ...
 Health Canal2 weeks ago Incretin-based drugs do not increase risk of heart failure  News-Medical.Net1 month ago

Novo Nordisk - Growth In 'Diabesity' Treatment (Part 1 Of 2)

Novo Nordisk, the mega-cap Danish pharma company, is experiencing large and growing profits from its glucagon-like receptor agonist Victoza. This agent helps control diabetes, is approved for weight loss, and has also been combined with one of ...
 Seeking Alpha2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less